Over 179,000 blood cancer patient datasets have been identified and approx. 121,000 records are currently available for analysis on the HARMONY Big Data Platform.
We developed new tools where you can now explore data:
Click on the links below to gain access and start exploring.
The HARMONY Data Exploration tool has been developed to facilitate the visualization of baseline data to foster the generation of new research ideas. You can select the characteristics of the cohort that are interesting for your research idea and see the number of cases that are currently available within the HARMONY Big Data Platform.
The HARMONY Outcomes Prediction Calculator provides data-driven predictions to help clinicians decide if AML patients should be considered for allogeneic transplantation, especially in countries where targeted therapies are not available.
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
.jpg)
